Capecitabine-related neurotoxicity presenting with agraphia

Basit Öğe Kaydı
dc.authoridBayram, Ertugrul/0000-0001-8713-7613
dc.authoridiscan, dilek/0000-0002-0773-7780
dc.contributor.authorIscan, Dilek
dc.contributor.authorTolay, Rumeysa
dc.contributor.authorBayram, Ertugrul
dc.contributor.authorDemir, Turgay
dc.contributor.authorBicakci, Sebnem
dc.date.accessioned2024-11-07T13:32:45Z
dc.date.available2024-11-07T13:32:45Z
dc.date.issued2023
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractIntroduction Capecitabine is a pre-metabolite of 5-fluorouracil and is used as a chemotherapeutic agent. Among the common side effects of capecitabine, there are gastrointestinal side effects including nausea, vomiting, and diarrhea, and dermatological side effects including hand-foot syndrome and skin pigmentation change. However, neurological side effects of capecitabine are very rare. We describe herein a patient who developed neurological side effects in the form of agraphia and dysarthria on the 7th day of capecitabine treatment. Case Report A 34-year-old male patient, who was being followed up with the diagnosis of colon cancer, presented with speech and writing disorder that developed while under capecitabine treatment. Dysarthria and agraphia were detected in his neurological examination. Diffusion-weighted magnetic resonance imaging (MRI) revealed acute diffusion restriction in the splenium of the corpus callosum and at the level of the bilateral centrum semiovale. Brain MRI revealed symmetrical T2-weighted fluid-attenuated inversion recovery (T2-FLAIR) signal increases at the right temporoparietal medial, corpus callosum level, and bilateral white matter level. Management & Outcome The capecitabine treatment was terminated, and methylprednisolone treatment was administered and plasmapheresis procedure was carried out. Subsequently, significant improvement was observed in the clinical findings and neuroimaging. Discussion Capecitabine is used as an oral agent; thus, it provides ease of use. Neurological side effects associated with the use of capecitabine reportedly occur very rarely. The findings of this case demonstrated that leukoencephalopathy can be seen during the use of capecitabine, imaging results are very important in the diagnosis of leukoencephalopathy, and improvement can be achieved with the termination of the capecitabine treatment.
dc.identifier.doi10.1177/10781552221116329
dc.identifier.endpage749
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue3
dc.identifier.pmid35903929
dc.identifier.scopus2-s2.0-85135138037
dc.identifier.scopusqualityQ3
dc.identifier.startpage746
dc.identifier.urihttps://doi.org/10.1177/10781552221116329
dc.identifier.urihttps://hdl.handle.net/11480/15586
dc.identifier.volume29
dc.identifier.wosWOS:000832732100001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSage Publications Ltd
dc.relation.ispartofJournal of Oncology Pharmacy Practice
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20241106
dc.subjectAgraphia
dc.subjectcapecitabine
dc.subjectneurotoxicity
dc.titleCapecitabine-related neurotoxicity presenting with agraphia
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu